Clinical Trials

765 enrolled 16 charts 2 FDA

Prostatic Neoplasms, Castration-Resistant

NCT04497844 2026-04-13

AMPLITUDE

696 enrolled 15 charts 3 FDA

Metastatic Castration-sensitive Prostate Cancer

NCT04577833 2026-04-13

A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer

136 enrolled

Prostatic Neoplasms

NCT05021562 2026-04-13

A Study of Niraparib in Patients With Ovarian Cancer in Clinical Practice

Completed

354 enrolled

Ovarian Neoplasms

NCT05183984 2026-04-13

NIRVANA-1

390 enrolled

Ovarian Neoplasms

NCT06915025 2026-04-13

OVATION-3

Phase 3 Recruiting

500 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06392841 2026-04-08

HARMONY

Phase 2 Withdrawn

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT04037254 2026-04-06

Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring

Phase 1/2 Completed

22 enrolled 13 charts

Prostatic Neoplasms

NCT05335993 2026-04-03

A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

10 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06388733 2026-04-01

A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

Phase 3 Recruiting

450 enrolled

Brain Neoplasms, Glioblastoma

NCT05601440 2026-03-27

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

484 enrolled

Breast Neoplasms

NCT03601923 2026-03-25

Niraparib in Patients With Pancreatic Cancer

Phase 2 Completed

32 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT05198804 2026-03-18

A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer

Phase 1/2 Completed

117 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05694715 2026-03-17

Combination Therapy in Cancers With Mutations in DNA Repair Genes

Phase 1 Recruiting

24 enrolled

Neoplasm Metastasis

NCT06412120 2026-03-16

Study Evaluating Safety, Tolerability, and Metabolism of Niraparib

Phase 4 Recruiting

70 enrolled

Ovarian Neoplasms

NCT01042379 2026-03-13

I-SPY

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT03586661 2026-03-11

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

31 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Disease Progression

NCT02655016 2026-03-10

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

733 enrolled 21 charts 3 FDA

Phase EARLY_PHASE1 Active not recruiting

Ovarian Neoplasms

NCT05076513 2026-03-09

Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma

42 enrolled

Glioblastoma, Glioma

NCT04288687 2026-03-04

A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects

Phase 2 Completed

11 enrolled 13 charts

Prostate Adenocarcinoma

NCT04947254 2026-02-19

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

200 enrolled

Prostatic Neoplasms

NCT06433219 2026-02-18

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

63 enrolled

Phase 1/2 Active not recruiting

Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms

NCT05442749 2026-02-17

PARPi-PANC

Phase 2 Terminated

2 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT03830918 2026-02-12

Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy

59 enrolled

Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT04068753 2026-02-10

STAR

66 enrolled

Phase EARLY_PHASE1 Active not recruiting

Uterine Cervical Neoplasms

NCT05406700 2026-02-09

Niraparib In Recurrent IDH 1/2 Gliomas

16 enrolled

Glioma

NCT05718323 2026-02-06

RAISE

44 enrolled

Thoracic

SCLC,Extensive Stage

NCT05700721 2026-02-05

Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)

120 enrolled

Brain Neoplasms

NCT06086665 2026-02-04

REFIRM

Completed

850 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Ovarian Epithelial

NCT06077877 2026-02-02

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

42 enrolled

Neoplasms

NCT04170153 2026-01-30

Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

161 enrolled

Neoplasm Metastasis

NCT03768063 2026-01-29

IMbrella B

1,000 enrolled

Neoplasms

NCT04481113 2026-01-29

Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer

Phase 1 Completed

8 enrolled

Unilateral Breast Neoplasms

NCT04991480 2026-01-27

A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

Phase 1 Completed

93 enrolled

Phase 1/2 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT03368729 2026-01-23

Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer

46 enrolled

Breast Neoplasms

NCT04992013 2026-01-23

Niraparib in Tumors Metastatic to the CNS

20 enrolled

Neoplasm Metastasis, Central Nervous System Neoplasms

NCT03869190 2026-01-22

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Phase 1/2 Completed

272 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04544995 2026-01-21

Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)

Phase 1 Terminated

47 enrolled 43 charts

CNSSarcoma

Neoplasms, Neuroblastoma, Osteosarcoma

NCT04673448 2026-01-09

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

BreastGastrointestinalGynecologic

18 enrolled

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

NCT04221503 2026-01-08

Niraparib/TTFields in GBM

30 enrolled

Glioblastoma

NCT04475939 2026-01-08

ZEAL-1L

666 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05689021 2026-01-07

CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

8 enrolled

Prostatic Neoplasms

NCT03983993 2026-01-05

NIPAVect

26 enrolled 8 charts

Gastrointestinal

Colorectal Neoplasms

NCT03602859 2025-12-31

FIRST

1,400 enrolled 18 charts

Ovarian Neoplasms

NCT04592237 2025-12-23

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

120 enrolled

Prostatic Neoplasms

NCT02854436 2025-12-22

Galahad

Phase 2 Completed

289 enrolled 18 charts

Prostatic Neoplasms

NCT03651206 2025-12-19

ROCSAN

Phase 2/3 Recruiting

138 enrolled

GynecologicSarcoma

Ovarian Carcinosarcoma

NCT04701307 2025-12-15

Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

48 enrolled

EndocrineThoracic

Lung Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT05526989 2025-12-04

Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma

25 enrolled